European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires Live
Yesterday

European equities traded in the US as American depositary receipts were tracking higher late Thursday morning, rising 0.57% to 1,421.23 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis (CLLS) and biotech firm Evaxion Biotech (EVAX), which rose 4.3% and 3.1% respectively. They were followed by semiconductor company Sequans Communications (SQNS) and telecommunications company Ericsson (ERIC), which were up 2.8% and 1.7% respectively.

The decliners from continental Europe were led by medical device maker EDAP TMS (EDAP) and internet advertising firm Criteo (CRTO), which dropped 21% and 3.1% respectively. They were followed by accommodations booking company trivago (TRVG) and biopharmaceutical company DBV Technologies (DBVT), which lost 3% and 2.2% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical company NuCana (NCNA) and utilities company National Grid (NGG), which advanced 39% and 3.3% respectively. They were followed by telecommunications operator Vodafone Group (VOD) and medical device maker Smith & Nephew (SNN), which increased 2.5% and 2.1% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Mereo BioPharma Group (MREO), which fell 6.9% and 5.8% respectively. They were followed by biopharmaceutical company Adaptimmune (ADAP) and software firm Endava (DAVA), which were down 4.8% and 4.5% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10